Mesoblast Limited (NASDAQ:MESO)‘s stock had its “buy” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research note issued on Wednesday. They presently have a $20.00 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 186.12% from the stock’s current price.

The analysts wrote, “Mesoblast announced publication of data from a Phase 1b/2a study with mesenchymal precursor cells (MPCs) in patients with unilateral ACL reconstruction.””

MESO has been the topic of a number of other reports. Zacks Investment Research downgraded shares of Mesoblast Limited from a “buy” rating to a “sell” rating in a research note on Wednesday, May 17th. Maxim Group set a $14.00 target price on shares of Mesoblast Limited and gave the stock a “buy” rating in a research note on Thursday, May 25th. BidaskClub downgraded shares of Mesoblast Limited from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Finally, Credit Suisse Group set a $11.00 target price on shares of Mesoblast Limited and gave the stock a “hold” rating in a research note on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Mesoblast Limited presently has an average rating of “Hold” and a consensus target price of $12.70.

Shares of Mesoblast Limited (NASDAQ MESO) traded up 3.29% during trading on Wednesday, reaching $7.22. 20,351 shares of the company traded hands. The stock’s market capitalization is $574.31 million. Mesoblast Limited has a 52 week low of $4.01 and a 52 week high of $12.50. The firm has a 50 day moving average of $7.42 and a 200 day moving average of $8.21.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/16/mesoblast-limited-meso-rating-reiterated-by-cantor-fitzgerald.html.

A hedge fund recently raised its stake in Mesoblast Limited stock. Princeton Capital Management Inc. increased its position in shares of Mesoblast Limited (NASDAQ:MESO) by 15.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the period. Princeton Capital Management Inc. owned about 0.20% of Mesoblast Limited worth $1,398,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 2.92% of the company’s stock.

About Mesoblast Limited

Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.